Condition (MeSH)
Muscular Atrophy, Spinal
ClinicalTrials.gov lists 354 trials for Muscular Atrophy, Spinal or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 27.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
275 of the 354 trials are tagged with Muscular Atrophy, Spinal itself; the rest are tagged with a narrower condition beneath it.
When did Muscular Atrophy, Spinal trials start? (25)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 40
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 30 |
| 2025 | 24 |
| 2024 | 28 |
| 2023 | 25 |
| 2022 | 40 |
| 2021 | 25 |
| 2020 | 17 |
| 2019 | 22 |
| 2018 | 18 |
| 2017 | 16 |
Showing 10 of 25 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 36 trials starting in 2026 and about 28 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 44 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 188 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Muscular Atrophy, Spinal trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 24 |
| Phase 1/2 | 25 |
| Phase 2 | 42 |
| Phase 2/3 | 4 |
| Phase 3 | 28 |
| Phase 4 | 10 |
| Not applicable | 86 |
| Observational | 132 |
| Expanded access | 3 |
How many Muscular Atrophy, Spinal trials are recruiting? (11)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 11 |
| Recruiting | 62 |
| Enrolling by invitation | 6 |
| Active, not recruiting | 37 |
| Completed | 158 |
Showing 5 of 11 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Muscular Atrophy, Spinal trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Biogen | 27 |
| Hoffmann-La Roche | 17 |
| Novartis Pharmaceuticals | 16 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 7 |
| Novartis Gene Therapies | 7 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Muscular Atrophy, Spinal? (7)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nusinersen | 24 |
| Risdiplam | 18 |
| Enzalutamide | 5 |
| onasemnogene abeparvovec | 5 |
| Bicalutamide | 4 |
Showing 5 of 7 drugs.
Interventions as named in the registry (8)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Onasemnogene Abeparvovec-xioi | 6 |
| Sham Procedure | 4 |
| Nusinersen Injectable Product | 4 |
| EXG001-307 injection | 3 |
| 4-Phenylbutyrate | 3 |
Showing 5 of 8 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Muscular Atrophy, Spinal trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 284 | 22 |
| Respiratory failure | 103 | 15 |
| Respiratory distress | 90 | 12 |
| Acute respiratory failure | 84 | 14 |
| Scoliosis | 61 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Muscular Atrophy, Spinal? (183)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study. | Neurology | 2025 | Yes |
| First-in-human study of epidural spinal cord stimulation in individuals with spinal muscular atrophy. | Nature medicine | 2025 | Yes |
| Wearable-Derived Patterns of Performance Fatigability During Gait in Spinal Muscular Atrophy. | Muscle & nerve | 2025 | Yes |
| REGISTRE SMA FRANCE: A nationwide observational registry of patients with spinal muscular atrophy in France. | Journal of neuromuscular diseases | 2025 | Yes |
| Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy. | The Journal of clinical investigation | 2025 | Yes |
Showing 5 of 183 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.